Sun Pharma targets scale with $11.75B Organon buyout
Synopsis
Sun Pharma has agreed to acquire Organon in a $11.75 billion all-cash deal, including debt. Organon operates in more than 140 countries with revenue of about $6.2 billion in 2025. The transaction adds scale in women’s health and biosimilars, amid broader consolidation across the global pharmaceutical sector.
Sun Pharma will acquire Organon for $11.75 billion, adding scale in women’s health and biosimilars. The deal expands global reach across established and emerging pharmaceutical markets.
Key Highlights
- Sun Pharma to acquire Organon in $11.75 billion all-cash deal including debt component
- Organon reported $6.2 billion revenue in 2025 across operations in over 140 countries
- Deal expands presence in women’s health, biosimilars, and established medicines segments
- Global pharma market exceeds $1.5 trillion, driven by specialty drugs and biologics growth
Sun Pharmaceutical Industries has agreed to acquire Organon & Co. in an all-cash transaction valued at $11.75 billion, including debt.
The agreement remains subject to regulatory approvals and customary closing conditions.
The transaction involves acquiring all outstanding shares of Organon. It is one of the largest outbound deals by an Indian pharmaceutical company and comes amid increased consolidation across the global drug industry.
Portfolio expansion across key therapies
Organon operates in more than 140 countries and reported revenue of about $6.2 billion in 2025.
Its portfolio spans women’s health, biosimilars, and established medicines across multiple therapy areas.
The acquisition adds scale in segments that continue to see steady demand. Women’s health treatments and biosimilars are gaining traction as healthcare systems focus on cost-effective therapies and broader access.
Market context and sector trends
According to an IQVIA report, the global pharmaceutical market exceeded $1.5 trillion in 2023, with specialty medicines and biologics driving growth. Biosimilars, which are lower-cost versions of biologic drugs, are expanding as patents on original drugs expire.
Recent transactions across the sector have reflected a shift toward acquiring established portfolios and specialty assets.
The Sun Pharma–Organon deal aligns with this trend of scaling global operations through acquisitions.
Financials and geographic reach
Sun Pharma reported over $5.4 billion in revenue in FY2024, with a strong presence in generics and specialty drugs.
Organon derives a large share of its revenue from developed markets, alongside operations in Latin America and Asia-Pacific.
Organon was spun off from Merck & Co. in 2021. The combined portfolio is expected to broaden Sun Pharma’s product mix across multiple regions.
FAQs
Q1. What is the size of the Sun Pharma–Organon deal?
The transaction is valued at $11.75 billion, including Organon’s existing debt.
Q2. What businesses does Organon operate in?
Organon focuses on women’s health, biosimilars, and established pharmaceutical medicines across global markets.
Q3. Why is this acquisition significant in the pharma sector?
It reflects ongoing consolidation and demand for scale in specialty drugs and biosimilars segments globally.
Q4. When is the deal expected to close?
The deal will close after regulatory approvals and customary conditions are completed; no exact timeline has been announced.
Follow Inspirepreneur Magazine for daily global business news.
Pooja Malik is a business journalist with over six years of experience covering startups, entrepreneurship, and emerging trends. She has previously worked with leading media platforms such as YourStory Media and BW BusinessWorld, where she reported on business, policy, and market developments. Currently, she serves as Editor at The Inspirepreneur Magazine, where she writes and edits stories across business, lifestyle, and travel, with a focus on clarity, accuracy, and reader relevance.
